Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Healios Grabs Worldwide Rights to Athersys’ Cell Therapy in ARDS
Tokyo-based biotech Healios said on October 11 that it has agreed with US partner Athersys to obtain exclusive global rights to its off-the-shelf cell therapy product MultiStem for the treatment of acute respiratory distress syndrome (ARDS). They previously concluded a…
To read the full story
Related Article
- Healios, Nobelpharma Reach No Deal on Cell Therapy MultiStem
January 16, 2025
- Healios Again Delays Definitive MultiStem Deal with Nobelpharma
October 1, 2024
- Healios Pushes Back Definitive MultiStem Deal with Nobelpharma
July 1, 2024
- Healios Snaps Up Assets after Athersys’ Bankruptcy Filing
April 5, 2024
- Healios, Nobelpharma Ink Basic Deal for Cell Therapy Alliance in ARDS
December 28, 2023
- Healios Bolsters Capital Alliance with Athersys, Gets Manufacturing License for Cell Therapy Product
August 10, 2021
BUSINESS
- Boehringer’s Japan Pharma Sales Up for 7th Straight Year, 10-Plus Launches Eyed by 2030
June 4, 2026
- Nitrosamine Detected in Viatris’ Jzoloft OD Tablets
June 4, 2026
- RaQualia, RIKEN Team Up on Drug Discovery Technologies
June 4, 2026
- AbbVie Japan Says Sales-Doubling Plan on Track as Revenue Climbs 13.5%
June 3, 2026
- FunPep, Crafton Join Forces on Therapeutic mRNA Vaccines
June 3, 2026
Japan is finally launching technical discussions on its cost-effectiveness assessment (CEA) system. A health ministry-funded research group is set to…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…